⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KALV News
KalVista Pharmaceuticals, Inc. Common Stock
Il Gruppo Chiesi acquisisce KalVista Pharmaceuticals, rafforzando il portafoglio globale nelle Malattie Rare
businesswire.com
KALV
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
businesswire.com
KALV
Form 8-K
sec.gov
ACOG
BIIB
SUPN
KALV
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
businesswire.com
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
KALV
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
businesswire.com
KALV
Form 8-K
sec.gov
KALV
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
businesswire.com
KALV
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
businesswire.com
KALV
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
businesswire.com
KALV